Randomized phase 2 trial of a PARP inhibitor TSL-1502 in germline BRCA-mutated, HER2-negative locally advanced/metastatic breast cancer
Bo Lan, Faliang Xu, Tao Sun, Fuming Qiu et autres
cn, us (code pays fourni par la source)
0 citations
Signal Transduction and Targeted Therapy